Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation

International Journal of Radiation Oncology, Biology, Physics
L FullerJ L Palmer

Abstract

The purpose of this study was to evaluate the possible effect of adjunctive involved field (IF) radiotherapy on long-term local control for patients with Ann Arbor Stage I-III diffuse large cell lymphoma (DLCL) who achieved a complete remission on a combined modality program which included cyclophosphamide, doxorubicin, vincristine, prednisone, and Bleomycin (CHOP-Bleo). One hundred and ninety patients with Ann Arbor Stage I-III DLCL were treated with CHOP-Bleo and radiotherapy. Analyses were undertaken to determine (a) response to treatment according to stage, extent of maximum local disease, and irradiation dose either < 40 Gy or > or = 40 Gy and (b) relapse patterns. A complete remission (CR) was achieved in 162 patients. Among patients who achieved a CR, local control was better for those who received tumor doses of > or = 40 Gy (97%) than for those who received < 40 Gy (83%) (p = 0.002.) Among those with extensive local disease, the corresponding control rates were 88% and 71%, respectively. A study of distant relapse patterns following a CR showed that the first relapse usually involved an extranodal site. Radiotherapy was an effective adjunctive treatment to CHOP-Bleo for patients with stage I-III DLCL who achieved a CR....Continue Reading

References

Nov 1, 1990·International Journal of Radiation Oncology, Biology, Physics·R ArriagadaM Tubiana
May 1, 1985·Annals of Internal Medicine·P Klimo, J M Connors
Apr 1, 1986·International Journal of Radiation Oncology, Biology, Physics·V T DeVitaS A Rosenberg
Nov 1, 1988·European Journal of Cancer & Clinical Oncology·R E TaylorR C Leonard
Feb 1, 1985·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J M CossetM Tubiana
Jan 1, 1985·Hematological Oncology·S H LevittG Frizzera
Nov 1, 1985·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S B SutcliffeM V Peters
May 11, 1974·British Medical Journal·I T MagrathN Harrison
Dec 1, 1984·American Journal of Clinical Oncology·J S KongJ A Sullivan
Feb 1, 1980·International Journal of Radiation Oncology, Biology, Physics·S MonfardiniA Lattuada
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project

❮ Previous
Next ❯

Citations

Jul 13, 2000·International Journal of Radiation Oncology, Biology, Physics·L N NguyenJ D Cox
Dec 1, 2001·International Journal of Radiation Oncology, Biology, Physics·N ShikamaN Hayabuchi
Feb 19, 2002·International Journal of Radiation Oncology, Biology, Physics·Richard W TsangBrian O'Sullivan
Dec 31, 2002·International Journal of Radiation Oncology, Biology, Physics·Naofumi HayabuchiYukihiro Toda
Mar 15, 1997·International Journal of Radiation Oncology, Biology, Physics·P DubeyJ D Cox
Dec 29, 1999·International Journal of Radiation Oncology, Biology, Physics·C S HaJ D Cox
Aug 26, 1998·American Journal of Clinical Oncology·C S HaJ D Cox
Apr 2, 2004·American Journal of Clinical Oncology·Steven J DiBiaseT H Wasserman
Apr 6, 1999·Radiology·C S HaJ D Cox
May 29, 1999·International Journal of Radiation Oncology, Biology, Physics·S S KamathN P Mendenhall
Sep 14, 2004·Leukemia & Lymphoma·Agustin AvilésSergio Cleto
Dec 27, 2005·International Journal of Radiation Oncology, Biology, Physics·Chandra MartensRichard Tsang
Feb 2, 2002·American Journal of Clinical Oncology·Jonathan H BriggsJames R Oleson
Mar 1, 1997·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·U KaiserK Havemann

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.